Management tracks: Ambys, Foghorn

Liver regenerative medicine company Ambys Medicines (Redwood City, Calif.) hired Jeff Jonker as president, CEO and a director. He succeeds Interim CEO Jeffrey Tong, who will become chairman. Jonker was president of NGM Biopharmaceuticals Inc. (South San Francisco, Calif.). Ambys launched in August with $140 million in funding from a series A round and an option partnership with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) (see “Ambys Launches With $140M from Series A, Takeda Deal”).

Foghorn Therapeutics Inc. (Cambridge, Mass.) hired Carl Decicco, former head of discovery of Bristol-Myers Squibb Co. (NYSE:BMY), as its first CSO. Decicco has contributed to the approval of over 20 drugs, including cancer drug Sprycel dasatinib from BMS and Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan). ...